Dáil Hears Urgent Pleas for Approval of Life-Sustaining Friedreich's Ataxia Drug Skyclarys Before Summer Recess
The Dáil Éireann heard urgent and emotional pleas on Wednesday for the HSE to approve Skyclarys, a drug that treats the rare and progressive neurological condition Friedreich's ataxia, before the house rose for its summer recess. The drug, which was approved by the European Commission in 2024, has not been made available to patients in Ireland after the HSE's National Centre for Pharmacoeconomics deferred a reimbursement decision, leaving families of those affected in a state of profound uncertainty and distress.
Background
Friedreich's ataxia is a rare inherited neurological condition that causes progressive damage to the nervous system, resulting in impaired muscle coordination, loss of sensation in the limbs, and, in many cases, heart disease. The condition typically presents in childhood or adolescence and is relentlessly progressive — most people with Friedreich's ataxia require a wheelchair within ten to fifteen years of diagnosis. There is no cure, and until recently, treatment options were limited to managing symptoms rather than addressing the underlying disease process.
Skyclarys — the brand name for omaveloxolone — represents a genuine breakthrough in the treatment of Friedreich's ataxia. It is the first drug to be approved specifically for the condition, and clinical trial data suggests it can slow the progression of neurological decline in patients. The European Medicines Agency granted approval for the drug in 2024, and it has since been approved for use in the United States and several European countries. For patients and families living with Friedreich's ataxia, the availability of Skyclarys represents a profound change in the landscape of the disease — not a cure, but a meaningful intervention that can preserve function and quality of life for longer.
The HSE's reimbursement process for new medicines is governed by the National Centre for Pharmacoeconomics, which assesses the clinical and cost-effectiveness of drugs before making recommendations on whether they should be funded by the state. The process is designed to ensure that public money is spent on treatments that deliver genuine value, but it has been criticised by patient groups and clinicians for being slow, opaque, and insufficiently responsive to the urgency of patients' needs — particularly in the case of rare diseases where the patient population is small and the evidence base may be limited.
Key Developments
The Dáil debate on Wednesday heard from several TDs who spoke on behalf of constituents and families affected by Friedreich's ataxia. The emotional weight of the contributions was considerable, with speakers describing the impact of the disease on young people and their families and the anguish of knowing that a treatment exists but is not available in Ireland. Tánaiste Simon Harris, responding to the debate, defended the HSE's reimbursement process as "clinically led" and guided by scientific evidence rather than bureaucratic inertia. He acknowledged the distress of those affected but indicated that the process must be allowed to run its course.
The Irish Times reported that the HSE's drugs group had deferred a decision on Skyclarys, a step that patient advocates described as deeply frustrating given the urgency of the situation for those living with the condition. The deferral means that Irish patients with Friedreich's ataxia continue to be denied access to a treatment that is available to their counterparts in other European countries, a disparity that has been highlighted repeatedly by the Friedreich's Ataxia Society of Ireland.
The Dáil's summer recess means that the issue will not be debated again in the house until September, adding to the sense of urgency felt by patient groups. The Friedreich's Ataxia Society of Ireland has called for the HSE to make an emergency decision on Skyclarys before the end of the summer, arguing that the delay is causing irreversible harm to patients whose condition continues to progress while they wait.
Why It Matters
The Skyclarys case is emblematic of a broader tension in Irish healthcare between the need for rigorous assessment of new medicines and the urgency of patients' needs. Ireland's reimbursement process has been criticised by patient groups across a range of conditions for being slower than comparable processes in other European countries. For rare diseases in particular, the standard pharmacoeconomic framework — which assesses cost-effectiveness based on quality-adjusted life years — can be poorly suited to conditions where the patient population is small and the disease burden is severe. The comparison with Northern Ireland is relevant: NHS patients in the North have access to Skyclarys through the NHS England approval process, meaning that patients on either side of the border are being treated differently for the same condition. This disparity is difficult to justify on clinical or ethical grounds.
Local Impact
Friedreich's ataxia affects an estimated 200 to 300 people in Ireland, a small but significant patient population concentrated in no particular geographic area. The Friedreich's Ataxia Society of Ireland, which is based in Dublin but serves members across the country, has been at the forefront of the campaign for Skyclarys approval. For the families of those affected — many of whom are young people in their teens and twenties — the delay in approval is not an abstract policy question but a daily reality with profound consequences for their loved ones' health and quality of life. Neurologists at St Vincent's University Hospital, the Mater University Hospital, and Cork University Hospital, who treat the majority of Irish patients with Friedreich's ataxia, have written to the HSE urging an expedited decision on reimbursement.
What's Next
The HSE's National Centre for Pharmacoeconomics is expected to return to the question of Skyclarys reimbursement in the coming months. The Friedreich's Ataxia Society of Ireland has requested an urgent meeting with the Minister for Health to discuss the timeline for a decision. If the HSE does not make a positive reimbursement decision before the end of 2026, patient groups have indicated they will consider legal action to compel the state to provide access to the drug. The issue is expected to be raised again in the Dáil when it returns from its summer recess in September.
